Moderna and Merck's personalised cancer vaccine has delivered positive Phase 3 results in patients with high-risk melanoma, raising hopes that the first treatment of its kind could reach the market as early as 2027.
The experimental vaccine, called intismeran autogene, reduced the risk of cancer returning or spreading when combined with Merck's immunotherapy drug Keytruda. The late-stage trial involved 1,137 patients whose stage IIB to IV melanoma had been surgically removed.
